Skip to main content

Peer Review reports

From: DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all- trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

Original Submission
20 Jan 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Publishing
13 May 2015 Editorially accepted
26 May 2015 Article published 10.1186/s12885-015-1432-5

You can find further information about peer review here.

Back to article page